(CL) Colgate-Palmolive - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1941621039

Toothpaste, Soap, Pet Food, Shampoo, Cleaner

Stock: Household Products
Age 49y

MCap 65,854m
Avg Vol 6.05M (488M USD)

Beta 0.029
Volatility 20.27%

EPS (Earnings per Share)

EPS CAGR: -45.30%
EPS Trend: -15.0%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 4.16%
Rev. Trend: 91.5%

Last SUE: 0.05
Qual. Beats: 0

Dividends

Dividend Yield	2.37%
Yield on Cost 5y	3.59%
Yield CAGR 5y	3.57%
Payout Consistency	99.6%
Payout Ratio	57.0%

Risk via 5d forecast
Volatility	20.3%
Value at Risk 5%th	33.0%
Relative Tail Risk	-1.17%

Reward TTM
Sharpe Ratio	-0.19
Alpha	-5.97
CAGR/Max DD	0.21

Character TTM
Hurst Exponent	0.384
Beta	0.029
Beta Downside	-0.027

Drawdowns 3y
Max DD	29.05%
Mean DD	9.98%
Median DD	7.99%

Description: CL Colgate-Palmolive December 02, 2025

Colgate-Palmolive (NYSE: CL) manufactures and sells a broad portfolio of oral, personal, home-care, and pet-nutrition products worldwide, organized into two operating segments: Oral, Personal & Home Care and Pet Nutrition. The consumer-care segment leverages well-known brands such as Colgate, Palmolive, Tom’s of Maine, Irish Spring, and Ajax, serving traditional retailers, e-commerce platforms, dentists and skin-health professionals, while the Pet Nutrition segment markets Hill’s Science Diet and Hill’s Prescription Diet through pet-supply stores, veterinarians and online channels.

Key recent metrics: FY 2023 net sales reached approximately $17.4 billion, with an adjusted operating margin of roughly 15 % and a dividend yield near 2.6 %, reflecting the company’s stable cash-flow generation in the defensive consumer-staples sector. Growth is being driven by price-inflation pass-throughs in emerging markets and a shift toward premium, health-focused products, while rising raw-material costs and global supply-chain constraints remain material risks.

If you want a data-driven deep-dive into CL’s valuation and forward-looking assumptions, a quick look at ValueRay’s analyst toolkit can provide useful context.

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (2.91b TTM) > 0 and > 6% of Revenue (6% = 1.21b TTM)

FCFTA 0.20 (>2.0%) and ΔFCFTA -0.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -2.27% (prev 1.20%; Δ -3.47pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.23 (>3.0%) and CFO 4.01b > Net Income 2.91b (YES >=105%, WARN >=100%)

Net Debt (7.14b) to EBITDA (4.81b) ratio: 1.48 <= 3.0 (WARN <= 3.5)

Current Ratio 0.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (810.2m) change vs 12m ago -1.50% (target <= -2.0% for YES)

Gross Margin 60.15% (prev 60.29%; Δ -0.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 117.2% (prev 119.9%; Δ -2.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 15.57 (EBITDA TTM 4.81b / Interest Expense TTM 270.0m) >= 6 (WARN >= 3)

Altman Z'' 8.10

(A) -0.03 = (Total Current Assets 6.04b - Total Current Liabilities 6.50b) / Total Assets 17.51b

(B) 1.54 = Retained Earnings (Balance) 27.05b / Total Assets 17.51b

warn (B) unusual magnitude: 1.54 — check mapping/units

(D) 1.51 = Book Value of Equity 24.63b / Total Liabilities 16.27b

Total Rating: 8.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 76.74

1. Piotroski 5.50pt

2. FCF Yield 4.72%

3. FCF Margin 17.13%

4. Debt/Equity 9.84

5. Debt/Ebitda 1.48

6. ROIC - WACC (= 31.14)%

7. RoE 545.1%

8. Rev. Trend 91.48%

9. EPS Trend -15.00%

What is the price of CL shares?

As of January 18, 2026, the stock is trading at USD 84.52 with a total of 6,949,898 shares traded.
Over the past week, the price has changed by +3.73%, over one month by +7.06%, over three months by +8.97% and over the past year by -2.25%.

Is CL a buy, sell or hold?

Colgate-Palmolive has received a consensus analysts rating of 3.77. Therefor, it is recommend to hold CL.

Strong Buy: 7
Buy: 6
Hold: 7
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the CL price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	87.5	3.5%
Analysts Target Price	87.5	3.5%
ValueRay Target Price	90	6.5%

CL Fundamental Data Overview January 13, 2026

P/E Trailing = 22.8235
P/E Forward = 21.097
P/S = 3.2768
P/B = 76.7268
P/EG = 3.1465
Revenue TTM = 20.10b USD
EBIT TTM = 4.20b USD
EBITDA TTM = 4.81b USD
Long Term Debt = 7.31b USD (from longTermDebt, last quarter)
Short Term Debt = 1.11b USD (from shortTermDebt, last quarter)
Debt = 8.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.14b USD (from netDebt column, last quarter)
Enterprise Value = 72.99b USD (65.85b + Debt 8.42b - CCE 1.28b)
Interest Coverage Ratio = 15.57 (Ebit TTM 4.20b / Interest Expense TTM 270.0m)
EV/FCF = 21.20x (Enterprise Value 72.99b / FCF TTM 3.44b)
FCF Yield = 4.72% (FCF TTM 3.44b / Enterprise Value 72.99b)
FCF Margin = 17.13% (FCF TTM 3.44b / Revenue TTM 20.10b)
Net Margin = 14.47% (Net Income TTM 2.91b / Revenue TTM 20.10b)
Gross Margin = 60.15% ((Revenue TTM 20.10b - Cost of Revenue TTM 8.01b) / Revenue TTM)
Gross Margin QoQ = 59.42% (prev 60.06%)
Tobins Q-Ratio = 4.17 (Enterprise Value 72.99b / Total Assets 17.51b)
Interest Expense / Debt = 0.80% (Interest Expense 67.0m / Debt 8.42b)
Taxrate = 22.78% (226.0m / 992.0m)
NOPAT = 3.25b (EBIT 4.20b * (1 - 22.78%))
Current Ratio = 0.93 (Total Current Assets 6.04b / Total Current Liabilities 6.50b)
Debt / Equity = 9.84 (Debt 8.42b / totalStockholderEquity, last quarter 856.0m)
Debt / EBITDA = 1.48 (Net Debt 7.14b / EBITDA 4.81b)
Debt / FCF = 2.07 (Net Debt 7.14b / FCF TTM 3.44b)
Total Stockholder Equity = 533.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 16.96% (Net Income 2.91b / Total Assets 17.51b)
RoE = 545.1% (Net Income TTM 2.91b / Total Stockholder Equity 533.2m)
RoCE = 53.63% (EBIT 4.20b / Capital Employed (Equity 533.2m + L.T.Debt 7.31b))
RoIC = 36.55% (NOPAT 3.25b / Invested Capital 8.88b)
WACC = 5.41% (E(65.85b)/V(74.27b) * Re(6.02%) + D(8.42b)/V(74.27b) * Rd(0.80%) * (1-Tc(0.23)))
Discount Rate = 6.02% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.91%
[DCF Debug] Terminal Value 87.29% ; FCFF base≈3.43b ; Y1≈3.79b ; Y5≈4.92b
Fair Price DCF = 171.3 (EV 145.22b - Net Debt 7.14b = Equity 138.08b / Shares 806.1m; r=5.90% [WACC]; 5y FCF grow 12.34% → 2.90% )
EPS Correlation: -15.00 | EPS CAGR: -45.30% | SUE: -4.0 | # QB: 0
Revenue Correlation: 91.48 | Revenue CAGR: 4.16% | SUE: 0.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.94 | Chg30d=-0.002 | Revisions Net=-8 | Analysts=12
EPS next Year (2026-12-31): EPS=3.84 | Chg30d=-0.004 | Revisions Net=-3 | Growth EPS=+5.1% | Growth Revenue=+3.5%

Additional Sources for CL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle